Du är här

2014-05-20

Novo Nordisk A/S: FDA schedules Advisory Committee meeting for liraglutide 3 mg for the treatment of obesity

Bagsværd, Denmark, 20 May 2014 -
Novo Nordisk today announced that the US Food and Drug Administration (FDA)
has informed the company that an FDA Advisory Committee meeting is
tentatively scheduled to be held on 11 September 2014 to discuss the New Drug
Application (NDA) for liraglutide 3 mg for the treatment of obesity. The NDA
was submitted to the FDA on 20 December 2013.

For further information-------------------------------------------------------------------
|Media: |
|Mike Rulis +45 4442 3573 mike@novonordisk.com |
|Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com |
|Investors: |
|Kasper Roseeuw Poulsen +45 3079 4303 krop@novonordisk.com |
|Jannick Lindegaard Denholt +45 3079 8519 jlis@novonordisk.com |
|Lars Borup Jacobsen +45 3075 3479 lbpj@novonordisk.com |
|Daniel Bohsen +45 3079 6376 dabo@novonordisk.com |
|Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com |
-------------------------------------------------------------------
Company announcement No 35 / 2014

Company announcement No 35 / 2014
http://hugin.info/2013/R/1787460/613749.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

HUG#1787460

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.